Literature DB >> 1380540

Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens.

M de Bueger1, A Bakker, J J Van Rood, F Van der Woude, E Goulmy.   

Abstract

We determined the tissue distribution of 7 human minor histocompatibility (H) Ag. Each of these Ag is defined by one or more MHC class I-restricted CTL clones, previously generated from PBL primed against minor H Ag by HLA-identical bone marrow transplantation (BMT). CTL-mediated lysis of tissue-derived cells and cultured cell lines was used as an in vitro assay for minor H Ag expression of several human tissues. The Ag HA-3 (HLA-A1-restricted), HA-4 (HLA-A2 restricted), HA-6 and HA-7 (HLA-B7 restricted), and the male-specific Ag H-Y (HLA-A2 and B7 restricted) were found to be expressed on cells of all tissues tested. In contrast, the HLA-A2-restricted Ag HA-1 and HA-2 were demonstrated on PHA-blasts, EBV-BLCL, purified T cells, B cells, monocytes, and immature thymocytes, but could not be demonstrated on skin-derived cultured fibroblasts, keratinocytes, melanocytes, cultured epithelial cells of kidney proximal tubili, and umbilical cord vein-derived endothelial cells. Incubation of the latter cell lines with rIFN-gamma, rTNF-alpha, and/or rIL-1 alpha, in concentrations shown to maximally increase their susceptibility to lysis by allo-MHC class I CTL, did not induce recognition by HA-1- and HA-2-specific CTL in vitro. These results indicate an ubiquitous tissue expression of the minor H Ag HA-3, -4, -6, -7 and H-Y in contrast to a to the hemopoietic cell lineage-restricted expression for HA-1 and HA-2. The heterogeneity in tissue expression of T cell-defined, class I-restricted non-MHC Ag implies that they might be derived from intracellular proteins with either an ubiquitous or a more specialized cell type-specific function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380540

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

Review 1.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

2.  Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies.

Authors:  Marleen M van Loenen; Renate de Boer; Renate S Hagedoorn; Esther H M van Egmond; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

3.  The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL.

Authors:  Anthony G Brickner; Anne M Evans; Jeffrey K Mito; Suzanne M Xuereb; Xin Feng; Tetsuya Nishida; Liane Fairfull; Robert E Ferrell; Kenneth A Foon; Donald F Hunt; Jeffrey Shabanowitz; Victor H Engelhard; Stanley R Riddell; Edus H Warren
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

4.  Expanding the immunotherapeutic potential of minor histocompatibility antigens.

Authors:  Eric Spierings; Els Goulmy
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

5.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.

Authors:  David B Miklos; Haesook T Kim; Katherine H Miller; Luxuan Guo; Emmanuel Zorn; Stephanie J Lee; Ephraim P Hochberg; Catherine J Wu; Edwin P Alyea; Corey Cutler; Vincent Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2004-12-21       Impact factor: 22.113

6.  Effector T cells require fatty acid metabolism during murine graft-versus-host disease.

Authors:  Craig A Byersdorfer; Victor Tkachev; Anthony W Opipari; Stefanie Goodell; Jacob Swanson; Stacy Sandquist; Gary D Glick; James L M Ferrara
Journal:  Blood       Date:  2013-09-17       Impact factor: 22.113

Review 7.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

8.  Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy.

Authors:  S Pion; P Fontaine; C Baron; M Gyger; C Perreault
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 9.  Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?

Authors:  Joseph Pidala; Claudio Anasetti
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

Review 10.  Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.

Authors:  Raya Mawad; Jack M Lionberger; John M Pagel
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.